News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Health Canada OKs Covidien plc (COV)'s Solitaire™ FR Revascularization Device



12/13/2012 7:09:02 AM

MONTREAL--(BUSINESS WIRE)-- Covidien, a leading global provider of healthcare products, today announced that the Solitaire™ FR Revascularization Device has been approved by Health Canada. The Solitaire FR device is used to restore blood flow to the brain in patients suffering from acute ischemic stroke.

"This new device is taking acute ischemic stroke care to a new level," said Dr. Mayank Goyal, Interventional Neuroradiologist at Foothills Medical Centre in Calgary, Canada, and Principal Investigator of Workflow and Imaging for the SWIFT-Prime (Solitaire FR as Primary Treatment for Acute Ischemic Stroke) study. "It clearly surpasses the first generation of clot-removing procedures, which were only moderately successful in reopening target arteries, and gives us a far superior tool for revascularization in stroke patients.”

An acute ischemic stroke can occur when a blood vessel that carries oxygen and nutrients to the brain is blocked by a clot and the flow of blood to the brain is interrupted. According to the Canadian Stroke Network’s Burden of Ischemic Stroke (BURST) study, the healthcare costs for patients in just the first six months after they have a stroke is more than $2.5 billion a year in Canada.

“Stroke is a widespread public health issue, with approximately 50,000 Canadians experiencing a stroke annually,” said Stacy Enxing Seng, President, Vascular Therapies, Covidien. “Solitaire FR is intended to transform the way this potentially fatal and often debilitating condition is treated.”

The Solitaire FR device received CE Mark approval in Europe and has been sold in that region by Covidien since November 2009. Solitaire FR is also available in the U.S., where it received U.S. Food and Drug Administration clearance in March 2012.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20121213005241/en/

MULTIMEDIA AVAILABLE:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50506736&lang=en

Contact:

Vascular Therapies

David T. Young, 508-452-1644

Manager, External Communications

david.young@covidien.com

or

Bruce Farmer, 508-452-4372

Vice President

Public Relations

bruce.farmer@covidien.com

or

Cole Lannum, CFA, 508-452-4343

Vice President

Investor Relations

cole.lannum@covidien.com

or

Todd Carpenter, 508-452-4363

Director

Investor Relations

todd.carpenter@covidien.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES